Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Armored RNA Quant Zika Virus Control

Asuragen has launched its custom Armored RNA Quant Zika Virus target, which can be used to develop molecular assays. The company's Armored RNA Quant technology is the gold standard for reliable and traceable standards to develop molecular assays for virus quantitation, the company said. Developed in collaboration with Jan Felix Drexler, professor at the University of Bonn Medical Center and the German Center for Infection Research, the control is a multi-gene target designed using seven genes from the Zika Brazilian reference sequence KU321639.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.